EMEA-001984-PIP02-20

Table of contents

Key facts

Active substance
Sparsentan
Therapeutic area
Uro-nephrology
Decision number
P/0021/2021
PIP number
EMEA-001984-PIP02-20
Pharmaceutical form(s)
  • Tablet
  • Age-appropriate oral liquid dosage form
Condition(s) / indication(s)
Treatment of focal segmental glomerulosclerosis
Route(s) of administration
Oral use
Contact for public enquiries
Vifor (International) AG

Email: sparsentan_ra@viforpharma.com
Tel: +41588518000

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating